Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - September 2016

ADME PK

As well as being a contract research organization, Cyprotex spend considerable resource performing research into the development and testing of in vitro and in silico methods as alternatives to animal testing. In September, our scientists have been busy presenting this research. At Eurotox, Cyprotex presented three posters - two on 3D cell-based models and one on validation of an ocular model as part of the CON4EI (part of CEFIC) project. At the DMG meeting in London, we presented our research on skin metabolism. Our webinar on genotoxicity testing strategies also attracted a large audience. All of these resources are available to you below.

Other important announcements in September have included introduction of an additional 8 transporter assays, and expansion of our metabolite identification service for the analysis of human clinical samples. We are also delighted to welcome our new Director of US Operations, Dr Monica Metea, who joined the company on 26th September. The role will provide operational and scientific leadership to our Watertown, MA and Kalamazoo, MI facilities.

Cyprotex presents new research at Eurotox

Cyprotex presented three new posters at Eurotox from 4-7 September. Download them for free:

' Predicting neurotoxicity of the brain by normalising 3D multiplexed high content screening (HCS) data to brain tissue specific exposure levels'  

Download

'Predicting drug-induced liver injury by normalising liver microtissue high content screening data to in vivo tissue concentrations'

Download

'Consortium for in vitro eye irritation testing strategy: Short Time Exposure (STE) model'

Download

Cyprotex Presents New Research at Eurotox
 
New Director of US Operations

We are delighted to announce the appointment of Monica Metea, PhD as Director of US Operations. Monica will lead our sites at Watertown and Kalamazoo.

Read the press release
Director of US Operations, Monica Metea
 
Announcing new capabilities to analyze clinical samples

We are pleased to announce our new capabilities to perform metabolite identification studies on human clinical samples. Our wide array of bioanalytical platforms now includes two AB Sciex TripleTOF® 6600 instruments, which are ideal for this purpose.

Learn more
High resolution metabolite identification
 
Eight additional transporter assays now available

We now have services for an additional eight transporters (PEPT1, PEPT2, NTCP, OATP1A2, OATP2B1, OAT2, OAT4 and OCTN2). These complement our existing regulatory DDI transporter panel for P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1 and MATE2K.

Learn more
In vitro transporter assays
 
Watch our presentation on 'In vitro strategies for regulatory genotoxicity testing'

Cyprotex scientists Jamin Willoughby, PhD and Brandon Zeigler, PhD recently presented a webinar on best practices for regulatory genotoxicity testing with a focus on the Ames test, in vitro chromosomal aberration test and in vitro micronucleus test. The webinar is now available to watch.

Watch the presentation
In vitro strategies for regulatory genotoxicity testing
 
New presentation on skin metabolism

Understanding skin metabolism is important for any topically applied pharmaceutical or chemical as reactive or toxic metabolites can lead to skin sensitization or other adverse effects. Senior Research Scientist, Rachel Upcott-Gill, presented our research in skin metabolism on the 19th September 2016 at the Drug Metabolism Group Summer Meeting in London.

Download the presentation
Presentation on skin metabolism
 
Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close